Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer

Fig. 3

Immune cytokines scoring model (patients were divided into two groups by number of high levels of three cytokines - VEGF-A, IL-10 and TGF-β1, 0–1 vs. 2–3) from plasma and proportion of immune cells in malignant body fluid had a significant prognostic role in mGC. a Survival analysis according to the number of high levels of cytokines did not meet the statistical significance for overall survival (P = 0.1). b Patients with high levels of at least two cytokines showed significantly shorter OS than patients with zero or one cytokine at high level (median OS, 1.6 vs. 2.2 months, P = 0.032, c-e Patients with high proportion of CD8 T lymphocyte with memory marker (CD8CD45RO) and late activation marker (CD8HLA-DR) and CD3 T lymphocyte with PD-1 (CD3PD1) were associated with poor prognosis. f Patients with high number of FoxP3+ cells were significantly associated with favorable prognosis than mGC with low number of FoxP3+ cells in body fluid. mGC, metastatic gastric cancer. Kaplan Meier survival analysis was performed for overall survival

Back to article page